title: Role of the complement anaphylatoxin C5a-receptor pathway in atopic dermatitis in mice.
abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a genetic background. The C5a‑receptor (C5aR) pathway has been reported to be involved in AD; however, the precise pathogenesis remains to be elucidated. In the present study, the contribution of the C5aR pathway to AD in mice was investigated. A BALB/c mouse model of AD was induced by application of 2,4‑dinitrochlorobenzene (DNCB) onto hairless dorsal skin. Following DNCB application for 2 weeks, C5aR expression in skin tissue was assessed by reverse transcription quantitative polymerase chain reaction. C5aR expression in skin tissue was significantly increased in mice with AD. In an additional experiment, C5aR antagonist (C5aRA) intracutaneously injected in combination with DNCB treatment. The skin‑fold thickness, number of total infiltrating leukocytes and mast cells infiltrating in skin tissue were measured. Interleukin‑4 (IL‑4) and interferon‑γ (IFN‑γ) levels in skin tissue and IL‑4, IFN‑γ, histamine and immunoglobulin E (IgE) levels in serum were measured using ELISA. The skin‑fold thickness, numbers of total infiltrating leukocytes and mast cells in skin tissue, as well as levels of IL‑4, IFN‑γ, histamine and IgE were significantly increased in mice with AD. However, simultaneous treatment with C5aRA significantly attenuated increases in skin fold thickness and the numbers of total infiltrating leukocytes and mast cells in skin tissue. Treatment with C5aRA also decreased IL‑4 and IFN‑γ levels in skin tissue, as well as the levels of IL‑4, IFN‑γ, histamine and IgE in the serum. In conclusion, C5aRA inhibited AD in mice, possibly through suppression of the C5aR‑mediated cascade action of mast cells.
authors: Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors: Lin
authors: L
authors: Dang
authors: Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors: Lei
authors: L
authors: He
authors: Department of Pathology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, P.R. China.
authors: Yan
authors: Y
authors: Wang
authors: Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors: Jikui
authors: J
authors: Xiong
authors: Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors: Bingxue
authors: B
authors: Bai
authors: Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China.
authors: Yuzhen
authors: Y
authors: Li
mesh_terms: D000818:Animals; D015936:Complement C5a / Q000276:immunology; D003876:Dermatitis, Atopic / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D004137:Dinitrochlorobenzene / Q000009:adverse effects; D004195:Disease Models, Animal; D015870:Gene Expression; D006632:Histamine / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood / Q000378:metabolism; D015847:Interleukin-4 / Q000097:blood / Q000378:metabolism; D008297:Male; D051379:Mice; D020556:Neutrophil Infiltration; D044087:Receptor, Anaphylatoxin C5a / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D004137:Dinitrochlorobenzene; D044087:Receptor, Anaphylatoxin C5a; D015847:Interleukin-4; D007073:Immunoglobulin E; D015936:Complement C5a; D006632:Histamine; D007371:Interferon-gamma
references: J Exp Med. 1987 Dec 1;166(6):1774-87
references: 2960773
references: J Exp Med. 1989 Dec 1;170(6):2081-95
references: 2531194
references: Curr Opin Immunol. 2009 Dec;21(6):666-78
references: 19828304
references: Br J Pharmacol. 2007 Oct;152(4):429-48
references: 17603557
references: J Invest Dermatol. 2005 Dec;125(6):1156-62
references: 16354185
references: J Immunol. 1989 Jul 1;143(1):334-9
references: 2786532
references: Allergy. 2004 Jun;59(6):561-70
references: 15147438
references: Allergy. 2004 Aug;59 Suppl 78:25-9
references: 15245353
references: Exp Gerontol. 2001 Jul;36(7):969-87
references: 11404045
references: Am J Pathol. 1993 Jun;142(6):1848-57
references: 8506953
references: Mol Med Rep. 2010 Jan-Feb;3(1):83-7
references: 21472204
references: J Allergy Clin Immunol. 2013 Feb;131(2):541-8.e1-9
references: 22728083
references: Int Immunopharmacol. 2012 Jan;12(1):158-68
references: 22155625
references: Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):382-6
references: 17873576
references: Immunology. 1985 Dec;56(4):575-84
references: 3935571
references: J Leukoc Biol. 2010 Jun;87(6):965-75
references: 20089669
references: J Immunol. 1999 Jan 15;162(2):1056-63
references: 9916733
references: Lab Invest. 1998 Dec;78(12):1615-23
references: 9881961
references: J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S86-93
references: 15968268
references: Allergy. 1993 Jan;48(1):1-5
references: 8457021
references: Immunol Lett. 1993 Jun;36(3):301-4
references: 8396560
references: Eur J Pharmacol. 2005 Nov 7;524(1-3):149-54
references: 16259975
references: Mol Med Rep. 2014 Jul;10(1):45-52
references: 24789665
references: J Invest Dermatol. 2001 Oct;117(4):977-83
references: 11676841